Filing Flows › Altimmune (ALT) › Q4 2025 › vs Q3 2025
Altimmune (ALT) Q4 2025 vs Q3 2025 (quarter over quarter)
Altimmune's revenue rose $21K (+420%) from $5K in Q3 2025 to $26K in Q4 2025.
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $26K | $5K | $21K | +420% |
| Other income, net | $1.5M | $1.8M | −$310K | -17% |
| Net loss | $27.4M | $19.0M | $8.3M | +44% |
| Costs & expenses | $28.9M | $20.9M | $8.1M | +39% |
| Operating costs | $28.9M | $20.9M | $8.1M | +39% |
| Research & development | $18.4M | $15.0M | $3.4M | +23% |
| General & admin | $10.5M | $5.9M | $4.6M | +78% |
| Operating cash sources | $27.4M | $19.0M | $8.3M | +44% |
| Depreciation | $26K | $27K | −$1K | -4% |
| Share-based compensation | $4.9M | $3.6M | $1.4M | +39% |
| Working capital & other | $2.9M | $3.5M | −$593K | -17% |
| Cash used in operations | $19.4M | $11.9M | $7.6M | +63% |
| Net loss absorbed | $27.4M | $19.0M | $8.3M | +44% |
Questions
How much did Altimmune's revenue grow quarter over quarter in Q4 2025?
Altimmune's revenue rose $21K (+420%) from $5K in Q3 2025 to $26K in Q4 2025.